Peter L. Choyke, MD, FACR, discusses recent developments in imaging for prostate cancer.
Peter L. Choyke, MD, FACR, chief, Molecular Imaging Branch, senior investigator, head, Imaging Section, National Cancer Institute, discusses recent developments in imaging for prostate cancer.
For a number of years, imaging modalities for prostate cancer weren't particularly intriguing diagnostic tools, Choyke says. Historically, bone scans and CT scans have been used, though both methods lacked the sensitivity needed to stage these patients.
Recently, however, numerous novel PET agents have dramatically improved the sensitivity for detecting metastatic or recurrent sites of prostate cancer, explains Choyke. It is now known that even in cases of very low prostate-specific antigen recurrences, sites of disease can be reliably detected using this modern method, Choyke concludes.